Article Text

PDF
In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas
  1. Z-D Jiang1,
  2. H L DuPont1,2,3,4,
  3. M La Rocco5,
  4. K W Garey6,7
  1. 1Center for Infectious Disease, University of Texas School of Public Health, Houston, Texas, USA
  2. 2Internal Medicine, University of Texas Medical School, Houston, Texas, USA
  3. 3Internal Medicine, Baylor College of Medicine, Houston, Texas, USA
  4. 4Internal Medicine, St Luke's Episcopal Hospital, Houston, Texas, USA
  5. 5Hospital Vice President Office, St Luke's Episcopal Hospital, Houston, Texas, USA
  6. 6Pharmacy, St Luke's Episcopal Hospital, Houston, Texas, USA
  7. 7Pharmacy, University of Houston, Houston, Texas, USA
  1. Correspondence to Zhi-Dong Jiang, University of Texas School of Public Health, 1200 Herman Pressler, Room 739, Houston, TX 77030, USA; zhi-dong.jiang{at}sph.uth.tmc.edu

Abstract

Aim This was an in vitro study to analyse the susceptibility of Clostridium difficile isolates to rifampin and rifaximin.

Methods Stool samples from patients who had nosocomial diarrhoea and C difficile toxin B at a university hospital between August 2006 and December 2007 were cultured for C difficile. Susceptibility of C difficile isolates to rifaximin and rifampin was determined by agar dilution and E strips, respectively. C difficile isolates were analysed via PCR for genes encoding toxins A and B, for binary toxin (BT), and for partial deletions of the tcdC gene (tcdC-del).

Results Rifaximin exhibited high-level activity against 359 C difficile isolates, with MIC50 <0.01 μg/ml and MIC90 0.25 μg/ml; rifampin had MIC50 <0.002 μg/ml and MIC90 4 μg/ml. Among isolates analysed, 55 (15%) were positive for BT and tcdC-del. 28 (8% of 359) isolates were resistant to rifampin (≥32 μg/ml), of which 6 (2% of 359) were resistant to rifaximin and rifampin with MIC values ≥32 μg/ml. 2 of the 28 isolates resistant to rifampin were A+/B+/BT+/tcdC-del+, 5 were A+/B+/BT/tcdC-del+, 4 were A+/B+/BT+/tcdC-del, 13 were A+/B+/BT/tcdC-del, and 4 had no detectable toxin genes. Of the 11 isolates resistant to rifaximin alone, 1 was A+/B+/BT/tcdC-del+, 2 were A+/B+/BT+/tcdC-del, 6 were A+/B+/BT/tcdC-del, and 2 had no detectable toxin genes.

Conclusions The study demonstrates that rifaximin has high-level activity against C difficile in vitro. Determination of resistance to rifampin by E strip did not predict rifaximin resistance.

  • Antibiotics
  • genetics
  • toxin

Statistics from Altmetric.com

Footnotes

  • Funding Salix Pharmaceuticals, Inc., 1700 Perimeter Park Drive, Morrisville, NC 27560-8404, USA.

  • Competing interests Dr Jiang and Dr DuPont have received honoraria and grant support from Salix Pharmaceuticals, Inc.

  • Ethics approval This study was conducted with the approval of the Approval has been obtained from both The University of Texas and St. Luke's Episcopal Hospital.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.